HeartMate III Left Ventricular Assist Device (LVAD) Trial
Heart failure patients will be randomized to the HeartMate III LVAD or HeartMate II LVAD as either a bridge to transplant or destination therapy. The Heartmate II is already FDA approved for both uses.
U.S. ENDURANCE Destination Therapy Trial
This randomized trial will assess the HeartWare® Ventricular Assist System as destination therapy in advanced heart failure patients. Patients will be placed on either the HeartWare® or HeartMate II LVAD. HeartWare® is already approved for bridge to transplant.
Recover Right Trial/Right Heart Failure
Washington University and Barnes-Jewish Hospital have also participated in the Recover Right Trial evaluating the Impella RP. The Impella RP is a percutaneous heart pump that is implanted through a single access site in the patient's leg and deployed through the venous system, across the right side of the heart without requiring a surgical procedure. This pump is for temporary support and may be inside a patient for up to 14 days.